LivaNova recently announced its decision to discontinue investments into its Caisson Interventional transcatheter mitral valve replacement (TMVR) programme.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
